Compare Aurobindo Pharma with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs ASTRAZENECA PHARMA - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA ASTRAZENECA PHARMA AUROBINDO PHARMA/
ASTRAZENECA PHARMA
 
P/E (TTM) x 16.6 106.4 15.6% View Chart
P/BV x 3.1 31.1 9.9% View Chart
Dividend Yield % 0.3 0.0 -  

Financials

 AUROBINDO PHARMA   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-19
ASTRAZENECA PHARMA
Mar-18
AUROBINDO PHARMA/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs8301,278 64.9%   
Low Rs527883 59.7%   
Sales per share (Unadj.) Rs333.9228.4 146.2%  
Earnings per share (Unadj.) Rs40.410.4 389.4%  
Cash flow per share (Unadj.) Rs51.816.3 318.3%  
Dividends per share (Unadj.) Rs2.500-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs237.198.8 240.0%  
Shares outstanding (eoy) m585.9125.00 2,343.6%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.04.7 43.0%   
Avg P/E ratio x16.8104.2 16.1%  
P/CF ratio (eoy) x13.166.4 19.7%  
Price / Book Value ratio x2.910.9 26.2%  
Dividend payout %6.20-   
Avg Mkt Cap Rs m397,56927,008 1,472.1%   
No. of employees `00017.91.4 1,316.7%   
Total wages/salary Rs m25,8491,535 1,683.6%   
Avg. sales/employee Rs Th10,956.94,210.9 260.2%   
Avg. wages/employee Rs Th1,447.71,132.2 127.9%   
Avg. net profit/employee Rs Th1,324.3191.1 693.1%   
INCOME DATA
Net Sales Rs m195,6365,710 3,426.2%  
Other income Rs m1,553123 1,267.9%   
Total revenues Rs m197,1895,833 3,380.9%   
Gross profit Rs m39,519463 8,537.4%  
Depreciation Rs m6,680147 4,531.5%   
Interest Rs m2,6260-   
Profit before tax Rs m31,767438 7,252.8%   
Minority Interest Rs m270-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-8810-   
Tax Rs m7,269179 4,062.9%   
Profit after tax Rs m23,645259 9,125.8%  
Gross profit margin %20.28.1 249.2%  
Effective tax rate %22.940.8 56.0%   
Net profit margin %12.14.5 266.4%  
BALANCE SHEET DATA
Current assets Rs m153,6453,209 4,787.6%   
Current liabilities Rs m120,4292,070 5,819.2%   
Net working cap to sales %17.020.0 85.1%  
Current ratio x1.31.6 82.3%  
Inventory Days Days13572 186.9%  
Debtors Days Days6435 182.4%  
Net fixed assets Rs m103,909790 13,148.0%   
Share capital Rs m58650 1,171.8%   
"Free" reserves Rs m138,3222,419 5,717.4%   
Net worth Rs m138,9082,469 5,625.4%   
Long term debt Rs m1,8000-   
Total assets Rs m264,5444,605 5,744.2%  
Interest coverage x13.1NM-  
Debt to equity ratio x00-  
Sales to assets ratio x0.71.2 59.6%   
Return on assets %9.95.6 176.5%  
Return on equity %17.010.5 162.2%  
Return on capital %23.817.7 134.4%  
Exports to sales %49.60-   
Imports to sales %18.80-   
Exports (fob) Rs m97,091NA-   
Imports (cif) Rs m36,741NA-   
Fx inflow Rs m97,316300 32,487.5%   
Fx outflow Rs m40,5892,015 2,014.4%   
Net fx Rs m56,727-1,715 -3,307.0%   
CASH FLOW
From Operations Rs m16,22088 18,453.1%  
From Investments Rs m-28,768-94 30,735.4%  
From Financial Activity Rs m19,191NA-  
Net Cashflow Rs m6,656-6 -116,778.9%  

Share Holding

Indian Promoters % 54.1 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 8.0 0.3 2,650.0%  
FIIs % 27.7 15.7 176.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 9.1 112.1%  
Shareholders   69,601 12,856 541.4%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   ORCHID PHARMA LTD  CIPLA  ABBOTT INDIA  ALEMBIC LTD  WYETH LTD  

Compare AUROBINDO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Rallies 1,000 Points; Bajaj Finance, Titan & Tata Steel Surge Over 7%(12:30 pm)

Share markets in India are presently trading on a strong note after the government eased curbs on most economic activities, even as the lockdown in containment zones was extended till June 30.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 2.5% (Quarterly Result Update)

May 20, 2020 | Updated on May 20, 2020

For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Nov 6, 2019 | Updated on Nov 6, 2019

Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

6 Charts Showing the State of Indian Financial Markets in 2020(Sector Info)

May 26, 2020

Six charts showing how Indian financial markets have performed in 2020 so far...

This 'Essential Product' Smallcap is a Must Have for a 'Covid-19' Immune Portfolio(Profit Hunter)

May 19, 2020

This smallcap company needs no stimulus measures to do well in the long term.

What the RBI's Rate Cut Means for Options Traders(Fast Profits Daily)

May 25, 2020

The RBI governor has cut the repo rate to 4%. What does this mean for options traders? Find out in this video.

Which Stocks Should You Buy, Sell, and Hold in the Market Today?(Profit Hunter)

May 21, 2020

The coronavirus led uncertainty refuses to go away from the markets. Here's what retail investors should do with their stocks...

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Jun 1, 2020 02:31 PM

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - GLENMARK PHARMA COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS